Urology

Multi-day not better than single-day antibiotic at preventing UTI after BTX shot

4 days ago

Prophylactic antibiotic works to prevent the development of urinary tract infection (UTI) following intravesical OnabotulinumtoxinA (BTX) injection, with a multiple-day regimen being as effective as a single-day regimen, according to a study.

Transperineal more tolerable than transrectal prostate biopsy

Tristan Manalac, 5 days ago

Patients undergoing prostate biopsies see fewer urinary infections and septic complications when the procedure is performed through a transperineal (TP) rather than a transrectal (TR) route, according to a recent Singapore study. Both methods achieve comparable levels of diagnostic accuracy.

Short-course IV antibiotics should be considered for nonbacteraemic UTI in babies

6 days ago

In the treatment of young infants with nonbacteraemic urinary tract infection (UTI), administering intravenous (IV) antibiotics for less than 48 hours appears to work well in the absence of meningitis, with low rates of treatment failure and serious complications, according to a study.

Oral tebipenem pivoxil hydrobromide works against complicated UTI, acute pyelonephritis

16 May 2022

Oral tebipenem pivoxil hydrobromide appears to be as good as intravenous ertapenem in the treatment of patients with complicated urinary tract infection (UTI) and acute pyelonephritis, with the two having a similar safety profile, according to data from a phase III study.

MRI provides long-term prognosis of patients with biochemical recurrence

13 May 2022

Use of prostatectomy bed magnetic resonance imaging (MRI) can give out long-term prognostic information for assessing patients with biochemical recurrence following prostatectomy, reveals a recent study.

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.

Olaparib-abiraterone combo improves PFS in mCRPC

Roshini Claire Anthony, 16 Mar 2022

The combination of olaparib and abiraterone in the first-line setting improved radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), results of the phase III PROpel trial showed.

Continuing enzalutamide after progression improves PFS in mCRPC

Roshini Claire Anthony, 09 Mar 2022

In patients with metastatic castration-resistant prostate cancer (mCRPC) who experience disease progression while on enzalutamide treatment, continuing enzalutamide appears to improve progression-free survival (PFS), according to results of the phase IIIb PRESIDE trial.

Triplet therapy with darolutamide a potential new standard of care for mHSPC

Darolutamide add-on: A new standard of care for metastatic prostate cancer?

Pearl Toh, 06 Mar 2022

Adding darolutamide to androgen-deprivation therapy (ADT) plus docetaxel significantly increases overall survival (OS) in patients with metastatic, hormone-sensitive prostate cancer (mHSPC), according to the ARASENS* trial presented at the ASCO GUCS 2022.

Niraparib-abiraterone-prednisone combo improves multiple outcomes in HRR+ mCRPC

Roshini Claire Anthony, 04 Mar 2022

In patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations*, combining niraparib with abiraterone acetate plus prednisone (AAP) in the first-line setting improved radiographic progression-free survival (rPFS) and other outcomes, results of the phase III MAGNITUDE study showed.

High-dose ipilimumab augments nivolumab benefit for TCC

Audrey Abella, 01 Mar 2022

In the phase II TITAN-TCC* trial presented at ASCO GU 2022, the addition of ipilimumab to nivolumab led to improved responses in patients with pretreated (second/third line) advanced/metastatic or surgically unresectable transitional cell carcinoma (TCC).

Avelumab continues to show promise for bladder cancer

Audrey Abella, 28 Feb 2022

In individuals with advanced urothelial carcinoma (UC), a first-line maintenance treatment regimen comprising a combination of avelumab and best supportive care (BSC) provided better survival benefit than BSC alone, according to long-term and subgroup analyses of the phase III JAVELIN Bladder 100 trial presented at ASCO GU 2022.

Obesity may influence survival in metastatic castration-resistant prostate cancer

Roshini Claire Anthony, 08 Sep 2021

The obesity paradox, where obesity appears to confer a protective effect, was noted in metastatic castration-resistant prostate cancer (CRPC), with improved survival outcomes among obese patients with metastatic CRPC, according to a study from EAU21.